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ABSTRACT 
This survey includes practicing optometrists from nine therapeutic states, to 
which a total of 225 surveys were sent, requesting their treatment of five different 
ocular conditions. The purpose of the survey was to see if practicing optometrists use 
the same "treatment of choice" that are taught in optometry school. 
The data was compiled into primary drugs of choice, and the total number of 
times a drug was listed for a given condition. The five conditions used were: bacterial 
conjunctivitis, allergic conjunctivitis, epithelial corneal abrasion, anterior uveitis, and 
viral conjunctivitis. Corresponding drugs of choice were: Polytrim, Naphcon-A, 
Tobrex, Pred Forte with a cycloplegic, and Naphcon-A. Data is displayed in graphical 
and tabular form for ease of interpretation. 
INTRODUCTION 
There are currently 42 states in the United States where optometrists may be 
licensed to prescribe therapeutic agents to treat ocular conditions. Although the laws 
may differ from state to state, all optometry students are educated in the treatment of a 
vast array of ocular conditions. 
For most common ocular conditions, there exists a number of acceptable 
treatments. When diagnosing, it is helpful to learn about certain signs and symptoms, 
which help identify particular conditions; likewise, remembering a specific "treatment 
of choice" makes it easier to recall which therapeutic agent may be most useful for a 
given condition. There are usually many different therapeutic agents that could be used, 
although many physicians habitually rely on one in particular. 
The purpose of this study was to survey a number of practicing optometrists to 
see if a consensus exists as to what the drug of choice is for five different ocular 
conditions. In optometry school, there is little debate over what the proper treatment is 
for a given condition. When faced with learning volumes of material, it helps to 
remember one particular treatment that the majority of physicians would agree upon as 
acceptable. However, once in practice, it might not always be feasible to rely upon one 
particular agent. Laws differ from state to state and there is no guarantee that a given 
pharmaceutical will be included in the drug formulary approved for use by optometrists. 
It could also be the case that the preferred treatment taught in school is a relatively new 
one and the cost of that particular preparation is rather expensive; an optometrist might 
need to consider the patient's ability to pay when writing out the prescription. As many 
physicians can testify, it is not unusual for a patient to take a prescription to a 
pharmacy and choose not to have it filled when confronted with the cost. For that reason, 
it may be better to choose an agent that has been available longer and is less expensive; 
even if it may not be considered the treatment of choice for a given condition, it may still 
be an effective choice. 
A survey of practicing optometrists may provide insight into alternative methods 
of treating common ocular conditions. Due to the numerous pharmaceutical agents 
approved for optometric use, it could be helpful to determine if a clear favorite exists 
for a given condition. This could be especially useful for those new graduates who may 
not feel so confident when faced with writing those first few prescriptions. 
METHODS 
The survey consisted of a cover page explaining the nature of the study with the 
reverse side containing the questionnaire. The survey was mailed to 225 practicing 
optometrists in nine different states. Included with the survey was a stamped, self-
addressed envelope to promote completion of the survey. The optometrists were selected 
from the 1993 Blue Book of Optometry, from Florida, Indiana, Kansas, Kentucky, 
Maine, Nebraska, Ohio, Oregon, and Washington; states were chosen to represent a wide 
range of therapeutic privileges. Efforts were made to keep the survey questions neutral 
in tone. A copy of the survey instrument may be seen is Appendix A. 
The initial question directed the doctors to indicate their therapeutic certification 
status. The second question listed five common ocular conditions: bacterial 
conjunctivitis, allergic conjunctivitis, corneal epithelial abrasion, anterior uveitis, and 
viral conjunctivitis. These fairly common conditions can be treated by optometrists in 
the majority of the states that allow therapeutic privileges. The doctors were asked to 
list any or all of the therapeutic agents that they would use to treat the ocular conditions. 
If a given condition would be referred, the doctor was instructed to write in "NT" 
indicating that he or she would not treat this particular condition. 
A period of two months was allowed to pass to ensure that all completed surveys 
had been received. Statistical analysis was then performed. Certification status of 
respondents was calculated on a percentage basis. When analyzing particular conditions, 
if more than one therapeutic agent was listed, the first one written in was considered to 
be the primary treatment. The additional drugs listed were tallied and compared on the 
basis of what percentage of surveys that the agent was cited. The "drug of choice" was 
determined to be the one that was chosen most frequently as primary treatment. 
Analysis of the treatment of anterior uveitis was more difficult, as many doctors chose to 
use a combination of drugs in their treatment regimen. In this instance, totals and 
percentages for each method of treatment was calculated. 
RESULTS 
The number of surveys completed was 135 yielding a return rate of 60%. Of the 
original 225 surveys mailed, 25 were not delivered because addresses were no longer 
current, leaving the adjusted return rate at 67.5%. 
With respect to licensure status, 125 or 92.6% of the doctors surveyed had 
current therapeutic privileges in their state . Only three surveys , or 2.2%, were from 
optometrists who were currently seeking TPA certification. Seven optometrists 
responded that they were not TPA certified, nor did they have intention to become 
certified, which is 5.2% of the total. (See Graph 1) 
For each ocular condition listed in the survey, the percentages of optometrists 
who choose to treat the condition are included. The therapeutic agents are listed by 
percentage of optometrists who would make it their primary drug of choice, as well as 
the percentage of the total number of times the agent was listed for the specific condition. 
The names of the therapeutic agents contained herein, are in brand or trade name 
form (see Appendix B for a complete listing of all the drugs mentioned, with generic 
names and percentage concentration.) 
Bacterial conjunctivitis (non-specific) was the first condition listed on the 
survey. All 125 optometrists with TPA certification chose to treat it. With regards to 
primary drug of choice, Polytrim was rated number one. 30.3% of optometrists 
indicated this agent as their first line of defense. Tobrex and Gentamicin were second and 
third running at 29.5% and 23.7%, respectively. These three agents were clearly the 
first choice for most optometrists, accounting for a total of 83.5% of all responses. 
Ciloxan claimed 5.0%, while Ocuflox, Polysporin ointment and Sodium Sulfacetamide 
each received 2.5%. Erythromycin and Neosporin ointments were next, both at 1 .6%, 
and Blephamide at 0.8% rounds out the primary diagnosis. A graphical view of the 
primary drugs of choice are listed in Graph 2. The total number of times a drug was 
mentioned, (or total percentages} are listed in Table 1. Tobrex was the drug most often 
mentioned, followed by Gentamicin, Polytrim, and Ciloxan. 
Alleroic conjunctivitis was treated by all 125 optometrists with TPA 
certification. Naphcon-A was the clear choice for the primary treatment with 38 .1 %, 
followed by Acular and Alomide with 19.0% and 11.9%, respectively . Vasocon-A was 
next with 5.8%, while Flarex and artificial tears both had 4.8% of respondents. 
Livostin was next at 4.0%, cold compresses along with Albalon-A followed at 3.7%, 
leaving Pred Mild with 2.4% and Blephamide at 1.8%. A summary of the primary 
diagnoses are listed in Graph 3. As for total percentages, Naphcon-A and Acular were 
named on almost half of all surveys. (See Table 2 for a breakdown of total allergic 
conjunctivitis responses .) 
The next condition was epithelial corneal abrasion, and again, all 125 optometrists 
with TPA certification chose to treat this . Besides therapeutic agents listed by name, 
included are categories with anti-infectives (non-specific) in conjunction with a 
pressure patch, cycloplegic, steroid, and patch with cycloplegic, based on the responses 
that were given. The number one primary treatment was an anti-infective in combination 
with a patch at 19.8%, followed closely by Tobrex solution at 19 .0%. Gentamicin was 
next at 15.7%, and the combination of an anti-infective with cycloplegic ranked fourth at 
10.7%. Polysporin ointment had 9.9%, Polytrim 8.3%, followed by an anti-infective-
pressure patch/cycloplegic combination of 7.5%. An anti-infective in conjunction with a 
steroid comes next at 3.3%, while Ciloxan and Tobrex ointment both received 2.5%. 
Voltaren completes the responses with 0.8%. (See Graph 4 for a summary. ) Total 
percentages were in correlation with the primary diagnosis. (Table 3.) 
The next condition provided for the optometrists was anterior uveitis. In this 
case, five O.D.s of the 125 TPA certified chose not to treat. The leading treatment of 
anterior uveitis was a steroid in combination with a cycloplegic agent (non-specific), at 
58.3%. Pred Forte was chosen by 26.1 %, while cycloplegic alone accounted for 6.1 %. 
FML Forte was used by 5.2%, while Flarex and Tobradex each were used by 7.1% of the 
doctors responding. Tobrex alone resulted in the final 0.9% of the data. (A summary of 
the data is shown in Table 4.) 
Viral conjunctivitis was the last condition given to the optometrists, and all 125 
with TPA certification responded. However, 11.2% of the optometrists indicated that no 
treatment was necessary, with the exception of patient education. With this in mind, 
34.6% said that ocular lubricants would be their primary treatment, and 7.5% said cold 
compresses should be utilized. This totals 53.3% of optometrists who chose to not use 
therapeutic agents as a primary treatment of viral conjunctivitis. The remaining 
percentages of those who would treat with therapeutics breaks down as follows; 
Naphcon-A 13.1 %, Gentamicin 3.7%, Blephamide 2.8%, Maxitrol 2.8%, Polytrim 
2.8%, Vasocon-A 2.8%, FML 1.9%, Tobrex 1.9%, Tobradex 1.9%. The diagnosis did 
not specify whether the conjunctivitis had any herpetic involvement, and because of 
this, 12.2% of the responses were aimed toward herpes simplex virus. Of those, 
Viroptic was chosen by 7.5% and Vira-A was used by 4.7% for primary treatment. (A 
summary of findings is shown in Graph 5.) 
DISCUSSION 
The return rate of 67.5% was much higher than anticipated. When the survey 
was prepared, a 25% rate of return was expected. It might be concluded that the 
positive result was due to the widespread expansion of therapeutic privileges of 
optometrists in this country, and the corresponding change in the nature of how 
optometry is practiced. Nearly all the surveys returned were completed by TPA 
certified optometrists. Of those 135 surveys, 92.6% were from optometrists with 
therapeutic licenses, adding validity to the study. As expected, certified optometrists 
would be more likely to complete the survey, accounting for the high percentage. 
The results for treatment of bacterial conjunctivitis showed Polytrim as the 
antibiotic of choice followed closely by Tobrex and Gentamicin. When treating bacterial 
conjunctivitis, it is common practice to prescribe an antibiotic without first culturing 
to determine the causative microbe. Because the invading organism is unknown, a 
broad-spectrum antibiotic is advisable. 
When doctors were asked what their would be treatment for bacterial 
conjunctjvitjs, it was not specified whether or not the presentation was acute, hyper 
acute or chronic in nature. When not given that valuable information, one would expect 
many to use the "shotgun" approach and use a proven broad-spectrum antibiotic. 
Tobrex and Gentamicin are old standards in that they are both effective, broad-
spectrum antibiotics that have been in use for many years. As with all antibiotics, the 
longer a particular agent has been in use, the greater the likelihood of developing 
resistant organisms. Hence, Polytrim is rapidly becoming the drug of choice in 
treatment of bacterial conjunctivitis. 
Even though Polytrim was cited most frequently as primary treatment, after 
numbers were tallied , {regardless of order,either primary, secondary or tertiary), 
Tobrex was listed more times {54.1% of all surveys). Gentamicin was second having been 
cited on 46.7% of all surveys, with Polytrim third at 43.0%. The only other antibiotic 
that had significant mention was Ciloxan, which appeared in 23.0% of all surveys. 
Ciloxan is indicated primarily for treatment of corneal ulcers and is only indicated in the 
treatment of conjunctivitis that is a result of a staphylococcal infection.1 
When looking at the overall data relating to bacterial conjunctivitis, we could see 
that Tobrex and Gentamicin remain very popular antibiotics, even with the advent of 
Polytrim. Given that Polytrim has only been on the market for a very short time, it is 
certainly gaining favor rather quickly. The two older drugs are available in both 
solution· and ointment form, while Polytrim is currently only in solution. Also, as with 
any new drug, Polytrim is relatively expensive compared to the others. It is likely that 
it will continue to grow in its usage as acceptance of the drug becomes more widespread. 
When asked how they would treat alferoic conjunctivitis, doctors chose 
Naphcon-A as their drug of choice. Naphcon-A is a combination drug consisting of an 
antihistamine and a decongestant in solution. It was chosen as primary treatment in 
38.1% of all optometrists surveyed. Acular was second, being cited in 19.0% of all 
surveys. Acular is a non-steroidal anti-inflammatory agent and is indicated for the 
relief of ocular itching due to seasonal allergic conjunctivitis.2 Alomide came in third 
at 11 .9%. Alomide is a mast-cell stabilizer indicated in treatment of vernal 
conjunctivitis, vernal keratoconjunctivitis, and vernal keratitis.3 There were seven 
other drugs listed as a primary treatment for allergic conjunctivitis, none of which 
exceeded 6% of the sample. 
In the statistics for the total number of times a drug was cited, regardless of order, 
Naphcon-A was still the most popular at 49.6% of all surveyed. Acular and Alomide 
were much closer this time showing up on 47.4% and 35.6% of all surveys 
respectively. A conclusion that could be drawn is that these drugs are strongly 
considered as treatment but tend to be a second or third choice. A steroid, FML Acetate 
0.1%, was cited in 17.0% of all surveys. 
As with Tobrex and Gentamicin earlier, Naphcon-A is a proven drug having been 
in use for many years, and is relatively inexpensive. Acular and Alomide are both very 
new, less proven and .more expensive. Using Alomide to treat allergic conjunctivitis is 
actually an off-label use.4 
Since there was no indication as to the severity of the allergic conjunctivitis in 
question, it is not surprising that a variety of responses was received. A total of 8.5% 
of those surveyed would simply provide therapy consisting of cold compresses or 
artificial tears. 
When we surveyed doctors as to how they would treat an epithelial corneal 
abrasion, we received many different responses. Even though we did not ask for 
particular details as to the nature of the treatment plan (e.g .. combination of drugs, 
patching), some doctors volunteered a detailed treatment regimen and others did not. 
In regards to the particular antibiotics that were chosen, Tobrex was the most 
often cited, being listed in 21.5% of all surveys as the primary antibiotic used. 
Gentamicin was second at 15.7%, and surprisingly, Polytrim was a distant fourth at 
8.3% trailing Polysporin at 9.9%. Once again, the established drugs were still very 
popular and were used more than the newer ones. 
When we compared the total number of times each drug appeared on a survey, the 
order remained the same except Ciloxan became the fourth most frequently cited which 
replaced Polytrim. This may not be surprising to some as Ciloxan is very effective in 
the treatment of bacterial corneal ulcers. As a result, it could be deemed an effective 
prophylactic against development of a corneal ulcer from an abrasion. 
Of those surveyed, 20.7% stated they would treat the corneal abrasion with a 
combination of antibiotic and patching. Another 12.6% would use an antibiotic in 
combination with a cycloplegic (likely in case of secondary uveitis). A smaller number. 
8.1 %, chose to employ all three. Finally, 5.2% chose a steroid/antibiotic combination. 
Overall, 69% of doctors surveyed chose to employ an antibiotic for prophylaxis 
in their primary treatment of an epithelial corneal abrasion. Every doctor that 
completed the survey chose some form of pharmacological treatment when given the 
diagnosis of an epithelial corneal abrasion. 
When asked treatment for anterior uveitis, once again a variety of responses was 
received. An important point is that not all certified optometrists were permitted to 
treat anterior uveitis as part of their therapeutic privileges. (As our survey was 
anonymous, we did not track which states our responses came from.) Of the 125 
surveys completed by TPA certified optometrists, only 5 doctors said they would choose 
to refer the anterior uveitis for treatment. There is no guarantee that those 120 doctors 
who chose to treat the uveitis are actually permitted by state laws to treat the condition. 
The majority of those surveyed chose to treat the uveitis primarily with a 
combination of a steroid and cycloplegic. This accounted for 57.6% of all surveyed. 
Several doctors, 5.6%, chose to treat with a cycloplegic alone. Two doctors or 1 .6% of 
all surveyed, chose to use an antibiotic/steroid combination, namely Tobradex. 
A large percentage of those surveyed, 30.6%, chose to treat the anterior uveitis 
with a steroid alone. Of that group, 78.9% chose to use Pred Forte as their steroid of 
choice. FML Forte was second most popular chosen by 15.8%. FML Acetate 0.1% was 
third at 5.3% . 
Even though Pred Forte and FML Forte have been found to be virtually identical in 
their effectivity in treating ocular inflammation, Pred Forte is much more popular 
among doctors surveyed. 
It is rath€r surprising that when the standard of care for treating anterior 
uveitis calls for the use of a steroid in combination with a cycloplegic, a full 38.4% of 
doctors chose alternative treatmentS Once again, one might argue that the survey did not 
provide enough information regarding signs. symptoms or severity of the condition to be 
treated. One irrefutable point is that Pred Forte is the steroid of choice when treating 
anterior uveitis. 
When doctors were asked how they would treat viral conjunctivitis, no clear 
consensus resulted as to the primary drug of choice. Fourteen of the 125 surveyed 
(11.2%) chose tb merely educate the patient and not employ a therapeutic agent. 
Another 34.6 % chose to prescribe only artificial tears and 7.5% chose cold compresses. 
When we combine these three responses, 53.3% of those surveyed chose not to use a 
pharmacological agent to treat viral conjunctivitis. 
Typically, treatment of viral conjunctivitis is unsatisfactory and the condition 
usually resolves within two weeks even if left completely untreated.6 Topical steroids 
are contraindicated unless ocular inflammation is severe and the possibility of a herpes 
simplex infection has been excluded.? Given that, it is surprising that 1 0.2% of those 
surveyed chose to treat the viral conjunctivitis with either a steroid alone or in 
combination with an antibiotic. One would expect doctors not knowing the causative agent 
to choose the conservative approach and avoid use of a steroid altogether. 
Another odd finding is that 8.4% of all surveyed chose to treat the viral 
conjunctivitis with an antibiotic. Perhaps they would use an antibiotic because they 
wanted to ensure that the etiology of the conjunctivitis was actually viral and not of a 
bacterial nature. However, in the case of our survey, the doctors were provided the 
diagnosis which leaves one puzzled as to the choice of an antibiotic in this instance. 
Many doctors (13.1 %), chose to use Naphcon-A to treat the viral conjunctivitis. 
Normally, one would not think a drug indicated for treatment of allergic conjunctivitis 
would apply in the treatment of viral conjunctivitis. However. Naphcon-A is described 
as being "possibly" effective in relieving ocular inflammation and irritation of which 
both may be present in a viral conjunctivitis .8 
Two antiviral agents were cited as well. Viroptic was the most popular of the 
two, being chosen by 7.5% of doctors. Vira-A was cited in 4.7% of all surveys. Both 
agents are indicated in the treatment of ocular herpes simplex infections involving the 
cornea, and only the conjunctiva if the cornea is involved as well.9 Since we did not 
provide any additional information as to the nature of the conjunctivitis, some doctors 
may have assumed corneal involvement to be present. It is more likely that the doctors 
chose an off-label use of these two drugs to treat the conjunctivitis in the event that it 
may be due to a herpes-simplex virus. 
Conclusions 
The treatment of ocular disease with therapeutic agents is becoming an important 
aspect of the modern practice of optometry. This assumption is supported by the large 
percentage of doctors who took the time to complete the survey. The overall response 
rate was much higher than was expected. 
No shocking data was collected with regard to the particular drugs chosen in 
treatment of the ocular conditions. A recurring theme was that older drugs remain very 
popular and remain in widespread use. Also, newer agents are quickly becoming accepted 
as alternatives to the established ones. This survey was conducted with the thought that 
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it may be helpful to newly licensed O.D.s and others who may be interested in clinical 
therapeutic regimens employed by a broad base of practitioners. 
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Table 1 
BACTERIAL TABLE:% OF SURVEYS AGENT WAS LISTED 
AGENT NUMBER PERCENTAGE 
BACITRACIN I 2 1.5% I 
BLEPHAMIDE 3 2.2°/o 
CILOXAN i 31 I 23.0°/o 
ERYTl-IROMYCIN 3 I 2.2% 
GENTAMICIN 63 46.7o/o 
NEOSPORIN 7 5.2% 
OCUFLOX 1 0 ' 7.4% 
POLYSPORIN I 1 2 8.9°/o 
POLYTRIM I 58 43.0% 
Na SULFACETAMIDE 7 I 5.2% I ! 
TOBREX I I 73 I 54.1% 
' 
Table 2 
ALLERGY TABLE: 0/o OF SURVEYS AGENT WAS LISTED 
I 
AGENT I NUMBER I PERCENTAGE 
ACULAR 64 47.4% 
ALBALON-A 7 I 5.2°/o 
ALOMIDE 48 35.6% 
ART.TEARS 1 0 7.4% 
BLEPHAMIDE 2 1.5% 
COLDCOMP. 1 1 8.1% 
FlAREX 23 17.0% 
LIVOSTIN 1 6 11 .6% 
NAPHCON-A 67 I 49.6% 
PRED-MILD 1 3 I 9.6% 
VASOCON-A 1 3 I 9.6% 
VOL TAREN I 2 I 1.5% 
Table 3 
CORNEAL TABLE:% OF SURVEYS AGENT WAS LISTED 
I 
I 
DRUG I I NUMBER PERCENT" AGE ! 
I I 
CILOXAN 1 5 11.1% 
GENTAMICIN 23 17.0o/o 
Pa..YSPORIN 20 14.8°/o 
POLYrRIM 1 4 1 0.4°/o 
TOOREX 36 26.7°/o 
TOBREX(UNG) ! 8 5.9% 
VOL TAREN I 4 3 .0% 
ANTI-INFECTIVE/PATCH I l 28 20.7% I 
-
ANTI-INFECTIVE/CYCLOPLEGIC I i 1 7 I 12.6% 
ANTI-INFECTIVE/STEROl 0 I i 7 5 .2% I 
ANTI-INFECTIVEIPATCH/CYCLO. I 1 1 ! 8 .1% I 
Table 4 
PRIMARY TREATMENT OF ANTERIOR UVEITIS 
! 
I 
TREATMENT STRATEGY I PERCENTAGE I 
I 
i 
STEROID ONLY: 
Flarex 1.6% I I 
FML Forte 4.8% 
Pred Forte 24.0% I 
STEROID/CYCLOPLEGIC 53.6% 
. 
CYCLOPLEGIC ONLY I 5.6% I 
I 
ANTI-INFECTIVE/STEROID: I I 1 
Tobradex I 1.6% I 
I I 
ANTI-INFECTIVE ALONE: I 
Tobrex 0.8% 
I 
WOULD REFER I 8.0% I 
Appendix A 
Therapeutic Survey 
1. Certification Status: 
-please indicate your current status of therapeutic licensure by checking the appropriate box: 
[ ] currently licensed for therapeutics 
[ ] currently pursuing therapeutic licensure 
( ] not licensed for therapeutic and not pursuing licensure 
2. Survey 
-five ocular conditions have been diagnosed; please list any or all therapeutic agents you 
would use in your practice to treat each one, in the space provided. If your state permits treatment 
of the condition by optometrists, but you would choose not to treat it, please write "NT" in the 
space instead. 
A. Bacterial conjunctivitis (not cultured): --------------------
[ ] state law does not allow therapeutic treatment of this condition 
B. Allergic conjunctivitis:--------------------------
[ ] state law does not allow therapeutic treatment of this condition 
C. Epithelial corneal abrasion:------------------------
[ ] state law does not allow therapeutic treatment of this condition 
D. Anterioruveitis: ____________________________ __ 
[ ] state law does not allow therapeutic treatment of this condition 
E. Viral conjunctivitis: -------------------------------
[ ] state law does not allow therapeutic treatment of this condition 
Appendix B 
Brand Name. Generic Name. Form of Drug. Manufacturer 
Acular, ketorolac tromethamine 0.5%, solution, Allergan 
Albalon-A, naphazoline hydrocholride 0.05% and antazoline phosphate 0.5%, solution, Allergan 
Alomide, lodoxamide tromethamine 0.1 %, solution, Alcon 
Bacitracin, bacitracin 500 units/g, ointment, various manufacturers 
Blephamlde, sulfacetamide 10% with prednisolone acetate 0.2%, suspension and ointment, 
Allergan 
Ciloxan, ciprofloxacin hydrochloride 0.3%, solution, Alcon 
Dexamethasone, dexamethasone sodium phosphate 0.1%-0.05%, solution and ointment, various 
manufacturers 
Erythromycin, erythromycin 0.5%, ointment, various manufacturers 
Flarex. fluoromethalone acetate 0.1 %, suspension. Alcon 
FML Forte, fluoromethalone acetate 0.25%. suspension. Allergan 
Garamycin, gentamicin 0.3%, solution and ointment, various manufacturers 
Livostln, levocabastine hydrochloride 0.05%. solution, Ciba Opthalmics 
Maxitrol, polymyxin B 10.000 units with neomycin 3.5' mg/g and dexamethasone, suspension and 
ointment, Alcon 
Naphcon-A, naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%, solution, Alcon 
Neosporln. polymixin B 10,000 units with bacitracin 400 units/g and neomycin 3.5 mg/g, 
ointment, Burroughs Wellcome 
Ocuflox, ofloxacin 0.3%, solution, Allergan 
Polysporin, polymixin B and bacitracin, ointment, various manufacturers 
Pofytrlm, trimethoprim sulfate 0.1% and polymixin B sulfate 10,000 units/ml, solution, 
Allergan 
Pred Forte. predniso lone acetate 1.0%, suspension, Allergan 
Pred Mild, prednisolone acetate 0.12%, suspension. Allergan 
Sulfacetamide. sodium sulfacetamide 10%, solution and ointment, various manufacturers 
TobraDex, tobramycin 0.3% with dexamethasone 0.1%-0.3%, suspension and ointment, Alcon 
Tobrex, · tobramycin 0.3%, solution and ointment, Alcon 
Vasocon-A, naphazoline 0.055 and antazol ine 0.5%, so lution , lolab 
Vira-A, vidarabine 3.0%, solution, Parke Davis 
Viroptic. trifluridine 1.0%, solution, Burroughs Wellcome 
Voltaren , dic!ofenac 0.1%, solution, Ciba Opthalmics 
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